Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

Humacyte announced Q1 2026 financial results showing Symvess product revenue of $0.5M (up from $0.1M in Q1 2025) with 29 units sold. The company appointed industry veterans James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer to accelerate commercialization. Key upcoming milestone includes Phase 3 hemodialysis trial interim results on June 11, 2026. The company also received a $1.475M purchase commitment from Saudi Arabia and DoD funding for bioengineered blood vessels. Despite restructuring that reduced headcount by 25%, Humacyte expects $14.3M in cost savings for the remainder of 2026.

05/13/2026, 7:00 AM • GlobeNewswire

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

Humacyte announced that renowned vascular surgeon Dr. Todd E. Rasmussen has joined as Chief Surgical Officer. Dr. Rasmussen brings 28 years of military medical experience and current Mayo Clinic faculty status to support clinical adoption of Symvess and advance the company's bioengineered tissue pipeline toward regulatory approval.

05/12/2026, 8:00 AM • GlobeNewswire

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Humacyte reported $2.0 million in total revenues for 2025 with 61 Symvess units sold. The company announced a $1.475 million purchase commitment from Saudi Arabia, FDA submission in Israel, and U.S. Department of Defense funding authorization. Key upcoming milestone includes top-line interim results from the V012 Phase 3 hemodialysis study expected in Q2 2026, with planned BLA filing in H2 2026. The company ended 2025 with $50.5 million in cash and secured a $77.5 million credit facility.

03/27/2026, 7:00 AM • GlobeNewswire

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Humacyte published long-term clinical data showing Symvess, a bioengineered vascular conduit, maintained structural integrity over 36 months with 92.9% infection-free rates, 82.5% limb salvage at 24 months, and no unprovoked structural failures in extremity arterial trauma patients. The results represent the first prospective long-term data for an off-the-shelf biologic conduit in traumatic arterial repair where autologous vein grafts are not feasible.

12/22/2025, 8:00 AM • GlobeNewswire

Strong Earnings and Biotech Resilience Define the Midweek Momentum

Several biotech companies reported significant developments, including Kraig Labs' breakthrough in spider silk production, Salarius Pharmaceuticals' public offering, Humacyte's Q3 progress, and CorMedix's record quarterly earnings.

11/12/2025, 11:00 AM • GlobeNewswire

Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback

The Russell 2000 index reached an all-time high after the Federal Reserve signaled potential interest rate cuts, boosting small-cap stocks and providing cheaper borrowing opportunities for smaller companies.

09/18/2025, 3:08 PM • Benzinga

Humacyte Posts Q2 Revenue Miss

Humacyte reported Q2 2025 earnings with $0.30 million in GAAP revenue, falling short of $1.0 million analyst estimates. The company saw expanded hospital access for its lead product Symvess, with 82 civilian hospitals approved by quarter-end, and showed improved financial metrics through cost controls.

08/11/2025, 7:20 AM • The Motley Fool